

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22862-0003US1	Application No. 10/598,486
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date August 31, 2006	Group Art Unit 1636

<b>Non-Patent Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	1	Abiru et al., "Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells," Hepatology, 35:1117-24 (2002)
	2	Ferrandina et al., "Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study," Clin. Cancer Res., 9:4324-31 (2003)
	3	Sheng et al., "Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2," J. Clin. Invest., 99:2254-59 (1997)
	4	Zitvogel et al., "Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines," J. Exp. Med., 183:87-97 (1996)

Examiner Signature  /Amy Juedes/	Date Considered 01/15/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AJ/